The receptor tyrosine kinases: Role in cancer progression

Surgical Oncology Clinics of North America

Volumn 10, Issue 2, 2001, Pages 271-288

  Lamorte, L ^a   Park, M ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; ENZYME ACTIVATION; GENE ACTIVATION; GENE AMPLIFICATION; HUMAN; METASTASIS; MOLECULAR DYNAMICS; ONCOGENE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035019093     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30065-6     Document Type: Review

References (123)

1. Abe A. Emi N. Tanimoto M. Fusion of the platelet-derived growth factor receptor b to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution Blood 90 1997 4271 4277
2. Avet-Loiseau H. Li J. Facon T. High incidence of translocations t(11;14) (q13;q32) and t(4;14) (p16;q32) in patients with plasma cell malignancies Cancer Res 58 1998 5640 5645
3. Bargmann C.I. Hung M. Weinberg R. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 Cell 45 1986 649 657
4. Barinaga M. From bench top to bedside Science 278 1997 1036 1039
5. Barr F. Translocations, cancer and the puzzle of specificity Nature Genet 19 1998 121 124
6. Baselga J. Tripathy D. Mendelsohn J. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
7. Bishop J. Molecular themes in oncogenesis Cell 64 1991 235 248
8. Bongarzone I. Pierotti M. Monzini N. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma Oncogene 4 1989 1457 1462
9. Buolamwini J. Novel anticancer drug discovery Curr Opin Chem Biol 3 1999 500 509
10. Burfeind P. Chernicky C. Rininsland F. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo Proc Natl Acad Sci USA 93 1996 7263 7268
11. Camp R. Rimm E. Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma Cancer 86 1999 2259 2265
12. Campbell S. Khosravi-Far R. Rossman K. Increasing complexity of Ras signaling Oncogene 17 1998 1395 1413
13. Cappellen D. De Oliveira D. Ricol D. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nature Genet 23 1999 18 20
14. Carlson K. Dou S. Chi D. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B Proc Natl Acad Sci USA 91 1994 1579 1583
15. Carroll M. Tomasson M. Barker G. The TEL/platelet-derived growth factor beta receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways Proc Natl Acad Sci USA 93 1996 14845 14850
16. Chan J. Stampfer M. Giovannucci E. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study Science 279 1998 563 566
17. Chesi M. Nardini E. Brents L. Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 Nature Genet 16 1997 260 264
18. Cohen P. The development and therapeutic potential of protein kinase inhibitors Curr Opin Chem Biol 3 1999 459 465
19. Cooper C. Park M. Blair D. Molecular cloning of a new transforming gene from a chemically transformed human cell line Nature (London) 311 1984 29 33
20. Cooper J. Bowen-Pope D. Raines E. Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins Cell 31 1982 263 273
21. Derynck R. Goeddel D. Ullrich A. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors Cancer Res 47 1987 707 717
22. DiGiovanni J. Bol D. Wilker E. Constitutive expression of insulin-like growth factor-I in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion Cancer Res 60 2000 1561 1570
23. DiGiovanni J. Kiguchi K. Frijhoff A. Deregulated expression of insulin-like growth factor-I in prostate epithelium leads to neoplasia in transgenic mice Proc Natl Acad Sci USA 97 2000 3455 3460
24. Donis-Keller H. Dou S. Chi D. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 2 1993 851 856
25. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt Curr Opin Cell Biol 10 1998 262 267
26. Dunn S. Ehrlich M. Sharp N. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer Cancer Res 58 1998 3353 3361
27. Eguchi M. Eguchi-Ishimae M. Tojo A. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15) (pl3;q25) Blood 93 1999 1355 1363
28. el-Deiry W. Role of oncogenes in resistance and killing by cancer therapeutic agents Curr Opin Oncol 9 1997 79 87
29. Fan S. Wang J. Yuan R. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents Oncogene 17 1998 131 141
30. Fleming T. Saxena A. Clark W. Amplification or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors Cancer Res 52 1992 4550 4553
31. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Med 1 1995 27 31
32. Frisch S.M. Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis J Cell Biol 124 1994 619 626
33. Fugazzola L. Pierotti M. Vigano E. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer Oncogene 13 1996 1093 1097
34. Ghoussoub R. Dillon D. D’Aquila T. Expression of c-met is a strong independent prognostic factor in breast carcinoma Cancer 82 1998 1513 1520
35. Golub T. McLean T. Stegmaier K. The TEL gene and human leukemia Biochim Biophys Acta 1288 1996 M7 10
36. Golub T. Baker G. Lovett M. Fusion of PDGF receptor beta to a novel ets-like gene, in chronic myelomonoocytic leukemia with t(5;12) chromosomal translocation Cell 77 1994 307 316
37. Greco A. Mariani C. Miranda C. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain Mol Cell Biol 15 1995 6118 6127
38. Greco A. Pierotti M. Bongarzone I. Trk-T1 is a novel oncogene formed by the fusion of tpr and trk genes in a human papillary thyroid carcinoma Oncogene 7 1992 237 242
39. Grieco M. Santoro M. Berlingieri M. PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 60 1990 557 563
40. Guasch G. Mack G. Popovici C. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8pl2 stem cell myeloproliferative disorder with t(8;9)(pl2;q33) Blood 95 2000 1788 1796
41. Guy C. Webster M. Schaller M. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci USA 89 1992 10578 10582
42. Halaban R. Kwon B. Ghosh S. bFGF as an autocrine growth factor for human melanomas Oncogene Res 3 1998 177 186
43. Hall A. Rho GTPases and the actin cytoskeleton Science 279 1998 509 514
44. Hanahan D. Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
45. Hanahan D. Weinberg R. The hallmarks of cancer Cell 100 2000 57 70
46. Hankinson S. Willett W. Colditz G. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 1998 1393 1396
47. Harris A. Nicholson S. Sainsbury R. Epidermal growth factor receptor and other oncogenes as prognostic markers J Natl Cancer Inst (Monographs) 11 1992 181 187
48. Heldin C. Dimerization of cell surface receptors in signal transduction Cell 80 1995 213 223
49. Henry J. Hennessy C. Levett D. Int-2 amplification in breast cancer: Association with decreased survival and relationship to amplification of c-erbB-2 and c-myc Intl J Cancer 53 1993 774 780
50. Hermanson M. Funa K. Hartman M. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops Cancer Res 52 1992 3213 3219
51. Hirota S. Isozaki K. Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580
52. Hofstra R. Landsvater R. Ceccherini I. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma Nature 367 1994 375 376
53. Houldsworth J. Cordon-Cardo C. Ladanyi M. Gene amplification in gastric and esophageal adenocarcinomas Cancer Res 50 1990 6417 6422
54. Hubbard S. Mohammadi M. Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases J Biol Chem 273 1998 11987 11990
55. Ito T. Seyama T. Iwamoto K. Hayashi T. In vitro irradiation is able to cause RET oncogene rearrangement Cancer Res 53 1993 2940 2943
56. Jeffers M. Rong S. VandeWoude G. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis J Mol Med 74 1996 505 513
57. Jeffers M. Rong S. VandeWoude G. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network Mol Cell Biol 16 1996 1115 1125
58. Jin L. Fuchs A. Schnitt S. Expression of scatter factor and c-met receptor in benign and malignant breast tissue Cancer 79 1997 749 760
59. Klohs W. Hamby J. Antiangiogenic agents Curr Opin Biotech 10 1999 544 549
60. Klugbauer S. Lengfelder E. Demidchik E. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident Oncogene 11 1995 2459 2467
61. Klugbauer S. Lengfelder E. Demidchik E. A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident Oncogene 13 1996 1099 1102
62. Klugbauer S. Rabes H. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas Oncogene 18 1999 4388 4393
63. Knezevich S. Garnett M. Pysher T. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma Cancer Res 58 1998 5046 5048
64. Knezevich S. McFadden D. Tao W. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma Nature Genet 18 1998 184 187
65. Koochekpour S. Jeffers M. Rulong S. Met and hepatocyte growth factor/scatter factor expression in human gliomas Cancer Res 57 1997 5391 5398
66. Lengauer C. Kinzler K. Vogelstein B. Genetic instabilities in human cancers Nature 396 1998 643 649
67. Lewis T. Shapiro P. Ahn N. Signal transduction through MAP kinase cascades Adv Cancer Res 74 1998 49 139
68. Long L. Rubin R. Baserga R. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor Cancer Res 55 1995 1006 1009
69. Long L. Rubin R. Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type I insulin-like growth factor receptor Exp Cell Res 238 1998 116 121
70. Longley B. Tyrrell L. Lu S. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm Nature Genet 12 1996 312 314
71. Ma J. Pollak M. Giovannucci E. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 J Natl Cancer Inst 91 1999 620 625
72. Martin T. Phosphoinositides as spatial regulators of membrane traffic Curr Opin Neu-robiol 7 1997 331 338
73. Martin-Zanca D. Hughes S. Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences Nature 319 1986 743 748
74. Mazure N. Chen E. Yeh P. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression Cancer Res 56 1996 3436 3440
75. Mulligan L. Kwok J. Healey C. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 1993 458 460
76. Nagata H. Worobec A. Oh C. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder Proc Natl Acad Sci USA 92 1995 10560 10564
77. Nakajima M. Sawada H. Yamada Y. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 85 1999 1894 1902
78. Natali P. Nicotra M. Di Renzo M. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: Demonstration of the relationship to malignant melanoma tumor progression Br J Cancer 68 1993 746 750
79. Otsuka T. Takayama H. Sharp R. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype Cancer Res 58 1998 5157 5167
80. Park W. Dong S. Kim S. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas Cancer Res 59 1999 307 310
81. Pawson T. Protein modules and signalling networks Nature 373 1995 573 580
82. Pegram M. Lipton A. Hayes D. Phase II study of receptor-enhanced chemosen-sitivity using recombinant humanized anti-pl85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 1998 2659 2671
83. Popovici C. Zhang B. Gregoire M. The t(6;8)(q27;pll) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1 Blood 93 1999 1381 1389
84. Rabbitts T. Chromosomal translocations in human cancer Nature 372 1994 143 149
85. Rak J. Mitsuhashi Y. Bayko L. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis Cancer Res 55 1995 4575 4580
86. Richelda R. Ronchetti D. Baldini L. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene Blood 90 1997 4062 4070
87. Ro J. North S. Gallick G. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma Cancer Res 48 1988 161 164
88. Robertson S. Tynan J. Donoghue D. RTK mutations and human syndromes when good receptors turn bad Trends Genet 16 2000 265 271
89. Rodrigues G. Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase Mol Cell Biol 13 1993 6711 6722
90. Rodrigues G. Park M. Oncogenic activation of tyrosine kinases Curr Opin Genet Dev 4 1994 15 24
91. Rong S. Jeffers M. Resau J. Met expression and sarcoma tumorigenicity Cancer Res 53 1993 5355 5360
92. Rong S. Segal S. Anver M. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation Proc Natl Acad Sci USA 91 1994 4731 4735
93. Rosen E. Goldberg I. Regulation of angiogenesis by scatter factor EXS 79 1997 193 208
94. Rosenthal E. Johnson T. Allen E. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor-and scatter factor-stimulated invasion of carcinoma cells Cancer Res 58 1998 5221 5230
95. Ross T. Bernard O. Berger R. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGF β R) in chronic myelomonocytic leukemia with t(5;7)(q33;qll.2) Blood 91 1998 4419 4426
96. Salassidis K. Bruch J. Zitzelsberger H. Translocation t(10;14) (q11.2:q22.1) fusing the kinectin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma Cancer Res 60 2000 2786 2789
97. Schmidt L. Duh F. Chen F. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nature Genet 16 1997 6873
98. Schmidt L. Junker K. Nakaigawa N. Novel mutations of the MET proto-oncogene in papillary renal carcinomas Oncogene 18 1999 2343 2350
99. Schwab M. Amplification of oncogenes in human cancer cells Bioessays 20 1998 473 479
100. Sell C. Baserga R. Rubin R. Insulin-like growth factor-I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis Cancer Res 55 1995 303 306
101. Slamon D. Clark G. Wong S. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
102. Slamon D. Godolphin W. Jones L. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
103. Smith L. Shen W. Perruzzi C. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-I receptor Nat Med 5 1999 1390 1395
104. Sozzi G. Bongarzone I. Miozzo M. A t(10;17) translocation creates the RET/ PTC2 chimeric transforming sequence in papillary thyroid carcinoma Genes Chromosome Cancer 9 1994 244 250
105. Stambolic V. Mak T. Woodgett J. Modulation of cellular apoptotic potential: Contributions to oncogenesis Oncogene 18 1999 6094 6103
106. Takayama H. LaRochelle W. Sharp R. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor Proc Natl Acad Sci USA 94 1997 701 706
107. Taniguchi M. Nishida T. Hirota S. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors Cancer Res 59 1999 4297 4300
108. Thompson C. Apoptosis in the pathogenesis and treatment of disease Science 267 1995 1456 1462
109. Tomasson M. Williams I. Hasserjian R. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor Blood 93 1999 1707 1714
110. Valentinis B. Reiss K. Baserga R. Insulin-like growth factor-I-mediated survival from anoikis: Role of cell aggregation and focal adhesion kinase J Cell Physiol 176 1998 648 657
111. Veikkola T. Karkkainen M. Claesson-Welsh L. Regulation of angiogenesis by way of vascular endothelial growth factor receptors Cancer Res 60 2000 203 212
112. Webster M. Donoghue D. FGFR activation in skeletal disorders: Too much of a good thing Trends Genet 13 1997 178 182
113. Wells A. Tumor invasion: Role of growth factor-induced cell motility Adv Cancer Res 78 2000 31 101
114. Westermarck J. Kahari V. Regulation of matrix metalloproteinase expression in tumor invasion FASEB J 13 1999 781 792
115. Wong A. Bigner S. Bigner D. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification Proc Natl Acad Sci USA 84 1987 6899 6903
116. Wong A. Ruppert J. Bigner S. Structural alterations of the epidermal growth factor receptor gene in human gliomas Proc Natl Acad Sci USA 89 1992 2965 2969
117. Xia Z. Dickens M. Raingeaud J. Davis R. Greenberg M. Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis Science 270 1995 1326 1331
118. Xiao S. Nalabolu S. Aster J. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome Nature Genet 18 1998 84 87
119. Yamamoto T. Kamat N. Kawano H. High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines Cancer Res 46 1986 414 416
120. Yamashita J. Ogawa M. Yamashita S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer Cancer Res 54 1994 1630 1633
121. Yu D. Jing T. Liu B. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cipl, which inhibits p34Cdc2 kinase Mol Cell 2 1998 581 591
122. Yu H. Spitz M. Mistry J. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis J Natl Cancer Inst 91 1999 151 156
123. Zhou D. Casey G. Cline M. Amplification of human int-2 in breast cancers and squamous carcinomas Oncogene 2 1988 279 282